SCHEMBL6318008

SCHEMBL6318008

CC(C)(COCC(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
APLNR P35414 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
CA1 P00915 3/20 0.34
CA7 P43166 3/20 0.34
CA2 P00918 2/20 0.34
AKT1 P31749 1/20 0.33
LATS1 O95835 1/20 0.33
CTSK P43235 5/20 0.33
CTSS P25774 4/20 0.33
CA12 O43570 3/20 0.33
CA14 Q9ULX7 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89258 0.81 CA1 (0.38) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL20194090 0.80 APLNR (0.36) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL24700423 0.79 NPC1 (0.43) KMT2AMEN1TDP1CA1CA7
SCHEMBL22405497 0.79 TDP1 (0.42) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL24792665 0.78 AKT1 (0.32) APLNRTDP1CA1CA7CA2
SCHEMBL15243945 0.77 CNR2 (0.38) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL22123749 0.77 TDP1 (0.34) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL1401158 0.77 MEN1 (0.44) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL7923566 0.77 CA2 (0.42) KMT2AMEN1GAAAPLNRTDP1
SCHEMBL21738917 0.76 CTSK (0.35) KMT2AMEN1GAAAPLNRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US claimed
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL R&D INVEST S A (PT) 2022-12-22 US disclosed
EP-4031535-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
WO-2021055627-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL- BIOTECH INVESTMENTS, INC. (US) 2021-03-25 WO disclosed
EP-1184370-B1 Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 2005-09-14 EP disclosed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US disclosed
EP-1517894-A1 N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-03-30 EP disclosed
WO-2004005255-A1 N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ AND/ OR SEROTONIN REUPTAKE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-01-15 WO disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
EP-1184370-A2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
US-6274584-B1 PEPTIDE DERIVATIVES; BIOAVAILABILITY; ENZYME RESISTANCE; MILK AND WOOL PRODUCTION NOVO NORDISK A/S (DK) 2001-08-14 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-6127354-A FOR TREATMENT OF GROWTH DISORDERS OR TO STIMULATE PRODUCTION OF WOOL OR MILK NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
US-5922770-A NOVEL COMPOUNDS THAT STIMULATE THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 1999-07-13 US disclosed
EP-0923539-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-06-23 EP disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1998003473-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-01-29 WO disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels APOB, LDLR, LPL KMT2A 2953/4885MEN1 1006/4885GAA 1102/4885
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH2, ASAH1, GBA1 KMT2A 1118/4885MEN1 1132/4885GAA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.